Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

por Dakroub, Rayan, Huard, Solène, Hajj-Younes, Yara, Suresh, Samyuktha, Badran, Bassam, Fayyad-Kazan, Hussein, Dubois, Thierry
Publicado 2023

Expression, Localization and Prognosis Association of MEP50 in Breast Cancer

por Suresh, Samyuktha, Vinet, Mathilde, Dakroub, Rayan, Lesage, Laetitia, Ye, Mengliang, Fayyad-Kazan, Hussein, Nicolas, André, Meseure, Didier, Dubois, Thierry
Publicado 2022

Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers

por Vinet, Mathilde, Suresh, Samyuktha, Maire, Virginie, Monchecourt, Clarisse, Némati, Fariba, Lesage, Laetitia, Pierre, Fabienne, Ye, Mengliang, Lescure, Auriane, Brisson, Amélie, Meseure, Didier, Nicolas, André, Rigaill, Guillem, Marangoni, Elisabetta, Del Nery, Elaine, Roman‐Roman, Sergio, Dubois, Thierry
Publicado 2019

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer

por Suresh, Samyuktha, Huard, Solène, Brisson, Amélie, Némati, Fariba, Dakroub, Rayan, Poulard, Coralie, Ye, Mengliang, Martel, Elise, Reyes, Cécile, Silvestre, David C., Meseure, Didier, Nicolas, André, Gentien, David, Fayyad-Kazan, Hussein, Le Romancer, Muriel, Decaudin, Didier, Roman-Roman, Sergio, Dubois, Thierry
Publicado 2022